Sitagliptin, a dipeptidyl peptidase-4 inhibitor, increases the number of circulating CD34(+)CXCR4(+) cells in patients with type 2 diabetes - Aso, Y; Jojima, T; Iijima, T (Endocrine, 2015)
et al.